Tags

Type your tag names separated by a space and hit enter

Doctor, my patient has CDI and should continue to receive antibiotics. The (unresolved) risk of recurrent CDI.
Rev Esp Quimioter 2019; 32 Suppl 2:47-54RE

Abstract

Recurrence rate ranges from 12% to 40% of all cases of Clostridium difficile infection (CDI) and proposes an exceptional clinical challenge. Conventionally, treatment options of CDI have been limited to regimes of established antibiotics (eg, pulsed/tapered vancomycin) or "improvised" alternative antibiotics (eg. teicoplanin, tigecycline, nitazoxanide or rifaximin) occasionally even in combination, but faecal microbiota transplantation is emerging as a useful and quite safe alternative. In recent years, promising new strategies have emerged for effective prevention of recurrent CDI (rCDI) including new an-timicrobials (eg, fidaxomicin) and monoclonal antibodies (eg, bezlotoxumab). Despite promising progress in this area, difficulties remain for making the best use of these resources due to uncertainty over patient selection. This positioning review describes the current epidemiology of rCDI, its clinical impact and risk factors, some of the measures used for treating and preventing rCDI, and some of the emerging treatment options. It then describes some of the barriers that need to be overcome.

Authors+Show Affiliations

No affiliation info availableNo affiliation info availableNo affiliation info availableMiguel Salavert Lletí. Unidad de Enfermedades Infecciosas. Hospital Universitario y Politécnico La Fe; Valencia. Av. Fernando Abril Martorell, nº 106; 46026-Valencia. Spain. Salavert_mig@gva.es.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

31475811

Citation

Castro, I, et al. "Doctor, My Patient Has CDI and Should Continue to Receive Antibiotics. the (unresolved) Risk of Recurrent CDI." Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia, vol. 32 Suppl 2, 2019, pp. 47-54.
Castro I, Tasias M, Calabuig E, et al. Doctor, my patient has CDI and should continue to receive antibiotics. The (unresolved) risk of recurrent CDI. Rev Esp Quimioter. 2019;32 Suppl 2:47-54.
Castro, I., Tasias, M., Calabuig, E., & Salavert, M. (2019). Doctor, my patient has CDI and should continue to receive antibiotics. The (unresolved) risk of recurrent CDI. Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia, 32 Suppl 2, pp. 47-54.
Castro I, et al. Doctor, My Patient Has CDI and Should Continue to Receive Antibiotics. the (unresolved) Risk of Recurrent CDI. Rev Esp Quimioter. 2019;32 Suppl 2:47-54. PubMed PMID: 31475811.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Doctor, my patient has CDI and should continue to receive antibiotics. The (unresolved) risk of recurrent CDI. AU - Castro,I, AU - Tasias,M, AU - Calabuig,E, AU - Salavert,M, PY - 2019/9/3/entrez PY - 2019/9/3/pubmed PY - 2019/9/3/medline SP - 47 EP - 54 JF - Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia JO - Rev Esp Quimioter VL - 32 Suppl 2 N2 - Recurrence rate ranges from 12% to 40% of all cases of Clostridium difficile infection (CDI) and proposes an exceptional clinical challenge. Conventionally, treatment options of CDI have been limited to regimes of established antibiotics (eg, pulsed/tapered vancomycin) or "improvised" alternative antibiotics (eg. teicoplanin, tigecycline, nitazoxanide or rifaximin) occasionally even in combination, but faecal microbiota transplantation is emerging as a useful and quite safe alternative. In recent years, promising new strategies have emerged for effective prevention of recurrent CDI (rCDI) including new an-timicrobials (eg, fidaxomicin) and monoclonal antibodies (eg, bezlotoxumab). Despite promising progress in this area, difficulties remain for making the best use of these resources due to uncertainty over patient selection. This positioning review describes the current epidemiology of rCDI, its clinical impact and risk factors, some of the measures used for treating and preventing rCDI, and some of the emerging treatment options. It then describes some of the barriers that need to be overcome. SN - 1988-9518 UR - https://www.unboundmedicine.com/medline/citation/31475811/Doctor,_my_patient_has_CDI_and_should_continue_to_receive_antibiotics._The_(unresolved)_risk_of_recurrent_CDI L2 - http://seq.es/abstract/suppl2-32-47-54 DB - PRIME DP - Unbound Medicine ER -